These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 33259075)
1. Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax. Diao S; Nichols ED; DiNardo C; Konopleva M; Ning J; Qiao W; Maiti A; DiPippo AJ Am J Hematol; 2021 Mar; 96(3):E65-E68. PubMed ID: 33259075 [No Abstract] [Full Text] [Related]
2. Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia. Cheng FM; Tien JZ; Chen TT; Yeh SP; Lin CC Ann Hematol; 2020 Sep; 99(9):2193-2195. PubMed ID: 32621180 [No Abstract] [Full Text] [Related]
3. Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up. Shahswar R; Beutel G; Gabdoulline R; Koenecke C; Markel D; Eder M; Stadler M; Gohring G; Schlegelberger B; Trummer A; Krauter J; Thol F; Heuser M Ann Hematol; 2021 Feb; 100(2):595-599. PubMed ID: 32705308 [No Abstract] [Full Text] [Related]
4. Venetoclax with decitabine or azacitidine for AML. Das M Lancet Oncol; 2018 Dec; 19(12):e672. PubMed ID: 30392809 [No Abstract] [Full Text] [Related]
5. Hypomethylating agents and venetoclax in acute myeloid leukemia. DiNardo CD Clin Adv Hematol Oncol; 2021 Feb; 19(2):82-83. PubMed ID: 33596188 [No Abstract] [Full Text] [Related]
6. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Jonas BA; Pollyea DA Leukemia; 2019 Dec; 33(12):2795-2804. PubMed ID: 31628431 [TBL] [Abstract][Full Text] [Related]
7. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Maiti A; Qiao W; Sasaki K; Ravandi F; Kadia TM; Jabbour EJ; Daver NG; Borthakur G; Garcia-Manero G; Pierce SA; Montalbano KS; Pemmaraju N; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Takahashi K; Yilmaz M; Jain N; Kornblau SM; Andreeff M; Bose P; Ferrajoli A; Issa GC; Masarova L; Thompson PA; Rausch CR; Ning J; Kantarjian HM; DiNardo CD; Konopleva MY Am J Hematol; 2021 Mar; 96(3):282-291. PubMed ID: 33264443 [TBL] [Abstract][Full Text] [Related]
8. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome. Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931 [TBL] [Abstract][Full Text] [Related]
9. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Schuler E; Wagner-Drouet EM; Ajib S; Bug G; Crysandt M; Dressler S; Hausmann A; Heidenreich D; Hirschbühl K; Hoepting M; Jost E; Kaivers J; Klein S; Koldehoff M; Kordelas L; Kriege O; Müller LP; Rautenberg C; Schaffrath J; Schmid C; Wolff D; Haas R; Bornhäuser M; Schroeder T; Kobbe G; Ann Hematol; 2021 Apr; 100(4):959-968. PubMed ID: 33191481 [TBL] [Abstract][Full Text] [Related]
10. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis. Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400 [TBL] [Abstract][Full Text] [Related]
11. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301 [TBL] [Abstract][Full Text] [Related]
12. Venetoclax-induced panniculitis in an acute myeloid leukemia patient. Liao PW; Wang RC; Chen TC; Teng CJ Ann Hematol; 2021 May; 100(5):1333-1334. PubMed ID: 33439305 [No Abstract] [Full Text] [Related]
13. The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies. Otoukesh S; Salhotra A; Marcucci G; Forman SJ; Pullarkat V; Aldoss I Leuk Res; 2019 Sep; 84():106196. PubMed ID: 31377457 [No Abstract] [Full Text] [Related]
14. Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia. Arslan S; Zhang J; Dhakal P; Moran J; Naidoo N; Lombardi J; Pullarkat V; Stein AS; Marcucci G; Yaghmour G; Bhatt VR; Fathi AT; Aldoss I Am J Hematol; 2021 Mar; 96(3):E59-E63. PubMed ID: 33227142 [No Abstract] [Full Text] [Related]